1 / 27

IMPLEMENTATION OF THE BRAZILIAN HIV/AIDS ANTIRETROVIRAL PROGRAM AT A PUBLIC HEALTH POST: ADHERENCE TO PRESCRIBING GUIDEL

IMPLEMENTATION OF THE BRAZILIAN HIV/AIDS ANTIRETROVIRAL PROGRAM AT A PUBLIC HEALTH POST: ADHERENCE TO PRESCRIBING GUIDELINES AND TREATMENT CONTINUITY. Carmody ER*; Diaz T**; Starling P***; Beruth dos Santos AP***; Sacks HS* *Mount Sinai School of Medicine, New York, NY, USA

emele
Download Presentation

IMPLEMENTATION OF THE BRAZILIAN HIV/AIDS ANTIRETROVIRAL PROGRAM AT A PUBLIC HEALTH POST: ADHERENCE TO PRESCRIBING GUIDEL

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IMPLEMENTATION OF THE BRAZILIAN HIV/AIDS ANTIRETROVIRAL PROGRAM AT A PUBLIC HEALTH POST: ADHERENCE TO PRESCRIBING GUIDELINES AND TREATMENT CONTINUITY Carmody ER*; Diaz T**; Starling P***; Beruth dos Santos AP***; Sacks HS* *Mount Sinai School of Medicine, New York, NY, USA **Global AIDS Program, CDC, PAHO, Rio de Janeiro, Brazil ***Centro de Saúde Vasco Barcelos de Nova Iguaçu

  2. Background: • Since 1996, Brazilian public health system has provided free, universal access to antiretroviral (ARV) therapy for people infected with HIV • 95,000 patients received ARV in 2000 at $303 million • Drugs purchased from international companies and produced in national laboratories

  3. Background (continued): Evaluation necessary to: • ensure optimal delivery of medicines • prevent drug resistance at individual and population levels • appraise program as model for low to low-middle income countries with high HIV burden

  4. Setting: Centro de Saúde Vasco Barcelos de Nova Iguaçu • Public outpatient health post in suburb of Rio de Janeiro with onsite pharmacy and four HIV physicians • Patient population drawn from low socioeconomic status • Nova Iguaçu ranked 18th among municipalities for number of AIDS cases in Brazil

  5. Centro de Saúde Vasco Barcelos de Nova Iguaçu, Brazil

  6. Study Objectives: • Assess feasibility of collecting medical record and pharmacy data to evaluate the provision of ARVs • Determine practitioner adherence to Brazilian ARV treatment guidelines • Assess whether prescriptions were refilled in timely manner; explore patient characteristics associated with treatment lapses • Improve a public health post’s ARV program

  7. Methods: • Design: Retrospective pilot study • Data collection: Year 2000 medical record and pharmacy dispensation review of all active patients who first registered at clinic for HIV/AIDS care from 1/00-6/00 (n=67 of total 115 registered) • Data analyses: Frequency analyses, chi-square association tests, and logistic regression • Outcome measures: % patients on HAART, % drug regimens prescribed according to guidelines, % patients with medication lapses >1 month in 2000

  8. Results: Patient Demographics • 58.2% male (n=39); 41.8% female (n=28) • Age: mean=34.9; Range=20 to 70 • Education: 4.5% none; 48% 1-8 years; 15% 9-12 years; 33% n/a • Most common occupations: domestic servant, mechanic, carpenter, homemaker, manicurist, unemployed

  9. Patient Clinical Characteristics • 80.6% of sample had AIDS: clinical symptoms or CD4<350 as per Brazilian definition (n=54) • 85.1% were ARV naïve • Date of HIV+ diagnosis: • 2000: 50.7% • 1999: 38.8% • 1998 or earlier: 7.5%; N/a 3% • Mean initial CD4+ level 276 cell/mm3, initial viral load 237,517 copies/ml

  10. Antiretroviral Use • 88.1% of patients sampled were prescribed ARV in 2000 (n=59) • 30.5% of patients prescribed ARV changed regimens during 2000 (n=18)

  11. Type of Initial ARV Therapy • Dual combination: 28.8% • HAART: 71.2% NRTI=nucleoside analogue reverse transcriptase inhibitor, NNRTI=non-nucleoside reverse transcriptase inhibitor, PI=protease inhibitor

  12. Practitioner Adherence to Treatment Guidelines • No contraindicated regimens were prescribed • 3.4% of total sample received regimens inadequate for immunologic measures (n=2) • 55.9% patients were prescribed ARV before both immunologic or virologic parameters known (n=33)

  13. Average Monitoring Delays Between Request and Notification of Lab Results

  14. Treatment Lapses • 23.7% of sample lacked medication for >1 month (n=14) • Example: patient recorded as picking up 30-day supply 3/4/00 did not return until after 5/4/00 • Medication insufficiencies primarily due to patient failure to pick up prescriptions (n=11), less so to pharmacy shortages (n=3)

  15. Predictors of Medication Insufficiency in Multivariate Analysis • Women nearly 6 times more likely to experience medication insufficiencies than men (OR=5.81, CI 1.41-23.86) • Univariate association between medication insufficiencies and hospitalization in 2000 not significant in multivariate analysis • Not associated with patient age, baseline CD4 count, or prior ARV use in univariate or multivariate logistic regression models

  16. Discussion: • Conservative prescription of HAART in proportion to dual combination therapy: • Nova Iguaçu: 70% HAART • New York City: 89% HAART in 1998 (Sackoff JE et al, 2000) • High practitioner adherence to ARV guidelines • Nova Iguaçu: correct therapy in 57 of 59 initial treatments • U.S.: 85% provider adherence (Kaplan JE et al, 1999) • Medication insufficiencies suggest adherence short of 90-95% needed for optimal viral suppression

  17. Discussion: Factors Contributing to Medication Insufficiencies as Discussed with Practitioners and Pharmacist: • Patient non-adherence • Use of multiple drug manufacturers led to frequent changes in packaging, creating patient confusion • Drug shortages • Transportation hurdles • Manual feedback system to estimate demand (delays, calculation errors)

  18. Study Limitations: • Small sample size • High proportion of archived initial registrants (35%) • Liberal, non-specific measure for medication insufficiencies

  19. Conclusions: • Brazilian public health system is providing ARV treatment according to guidelines at this health post • Delays in monitoring were identified as source of potential mismatch between clinical status and treatment • Problems exist with maintaining treatment continuity, largely due to patient non-adherence • Some evidence obtained that resource-poor countries can deliver successful HIV treatment provided that antiretroviral drugs are made available

  20. Recommendations: • Improved lab capabilities are needed to shorten monitoring delays • Adherence interventions addressing women may reduce treatment lapses • Standardization of labeling may facilitate medication use • Further adherence research using more standard markers is required

  21. References: • Carmody ER, Diaz T, Starling P, Beruth dos Santos AP, Sacks HS. An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic. Tropical Medicine & International Health, 2003; 8: 378-385. • Ministerio da Saude. Recomendaçoes para terapia antiretroviral em adultos e adolescentes infectados pelo HIV—1999. Coordenaçao Nacional de DST e AIDS, Brasilia. (http://www.aids.gov.br). • Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. Journal of AIDS, 2000; 23: 178-183. • Kaplan JE, Parham DL, Soto-Torres L et al. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the Unites States. Journal of AIDS, 1999; 21: 228-235.

More Related